Seelos Therapeutics Inc SEEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SEEL is a good fit for your portfolio.
News
-
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
-
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
-
Seelos Therapeutics' stock slides 58% after trial of treatment for suicidal ideation has too few patients to meet endpoint
Trading Information
- Previous Close Price
- $0.29
- Day Range
- $0.28–0.31
- 52-Week Range
- $0.28–49.80
- Bid/Ask
- $0.29 / $0.30
- Market Cap
- $3.83 Mil
- Volume/Avg
- 540,211 / 444,240
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
Comparables
Valuation
Metric
|
SEEL
|
IMVT
|
EWTX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 5.87 | 3.77 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
SEEL
|
IMVT
|
EWTX
|
---|---|---|---|
Quick Ratio | 0.10 | 21.56 | 18.98 |
Current Ratio | 0.14 | 22.14 | 19.50 |
Interest Coverage | −506.73 | — | — |
Quick Ratio
SEEL
IMVT
EWTX
Profitability
Metric
|
SEEL
|
IMVT
|
EWTX
|
---|---|---|---|
Return on Assets (Normalized) | −305.66% | −43.33% | −24.36% |
Return on Equity (Normalized) | — | −47.83% | −25.87% |
Return on Invested Capital (Normalized) | — | −52.69% | −29.82% |
Return on Assets
SEEL
IMVT
EWTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qlrfwvrcr | Cssyp | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kqvjfhz | Mccjr | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dvxxrsvb | Bjffgj | $97.3 Bil | |
MRNA
| Moderna Inc | Wbdtjzdyj | Vtfm | $41.3 Bil | |
ARGX
| argenx SE ADR | Ybkxydh | Hybf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nvwnpdwd | Zpp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bpplxpsl | Jkfkhvy | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dtpksvttt | Szkvq | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kszfjcsrm | Njvmx | $12.6 Bil | |
INCY
| Incyte Corp | Xsbxgydzj | Vynmk | $11.6 Bil |